Investors

Investors

Accelerating the development of new therapies and improving the diagnosis and treatment of serious diseases, we deliver value for our investors and partners, as well as those whose lives we touch.


We Deliver at a Global Scale

Benefits for all stakeholders

The combination of Median’s ground-breaking technology and world-class expertise perfectly positions us to revolutionize the field of medical imaging, transforming data generation, management, and access all around the world. Benefiting patients, health professionals, our partners and investors.


Press Releases and Corporate Updates

Latest Press Release

Median Technologies, a world leading oncology clinical trial imaging services provider, becomes preferred vendor to another Top 3 pharmaceutical company.

Shareholding Structure as of December 31, 2023

Number of shares: 18,404,608

FURUI Medical Science Company Luxembourg8.2
Celestial Successor Fund LP7.0
Abingworth LLP (nominative and non nominative)5.2
Canon Inc5.2
Founders, Management, Employees6.1
Others68.3

Stock Market Data

Median Technologies is listed on Euronext Growth (ISIN: FR0011049824, ticker: ALMDT)

Analyst Coverage

Median Technologies is followed by the analysts listed below.

Any opinions, estimates, forecasts and recommendations regarding Median Technologies made by these analysts are their own. These opinions, estimates, forecasts and recommendations may or may not represent those of Median’s management.

Company

Analyst

Gilbert Dupont

Pierre Alexandre Desir

TP ICAP / Midcap

Claire Deray

Bryan, Garnier & Co

Maria Vara

Portzamparc

Clément Bassat

Financial Agenda

Next financial communication: annual results 2023 on April 25, 2024 after trading.

Regulatory Documents

UPCOMING Shareholder meeting

06/19/2024

Shareholders’ Ordinary and Extraordinary General Meeting


Other regulated information


Disclosure of Total Number of Voting Rights and Number of Shares in the Capital 

Investor Contacts